CLEARWATER, FL — NOVEMBER 11, 2021 – Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences:

The 12th Annual Craig-Hallum Alpha Select Conference

• Management will participate in virtual 1×1 meetings on Tuesday, November 16. There will be no formal presentation.

The Stifel 2021 Virtual Healthcare Conference

• Management will present on Wednesday, November 17 at 3:20 p.m. ET.

The Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

• Management will participate in virtual 1×1 meetings on Thursday, November 18. There will be no formal presentation.

The Piper Sandler 33rd Annual Virtual Healthcare Conference

• Management will participate in a virtual fireside chat, which will be available on demand beginning on Monday, November 22 at 10:00 a.m. ET. Management will also participate in investor meetings on Thursday, December 2.

Live audio webcasts of the presentations will be provided under the ‘Company Events’ section of the Apyx Medical Corporation investor relations website at https://apyxmedical.com/investor_relations/. Archives of the webcasts will be available for replay following the conferences.

About Apyx Medical Corporation
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. Renuvion offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Investor Relations Contact
Westwicke Partners on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com